Compare · BBNX vs BSX
BBNX vs BSX
Side-by-side comparison of Beta Bionics Inc. (BBNX) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.39B, about 117.1x BBNX ($618.1M).
- Over the past year, BBNX is down 26.9% and BSX is down 50.8% - BBNX leads by 23.9 points.
- BBNX has been more active in the news (17 items in the past 4 weeks vs 12 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 16 for BBNX).
- Company
- Beta Bionics Inc.
- Boston Scientific Corporation
- Price
- $14.19+2.01%
- $49.28+1.17%
- Market cap
- $618.1M
- $72.39B
- 1M return
- +47.20%
- -8.60%
- 1Y return
- -26.89%
- -50.75%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 17
- 12
- Recent ratings
- 16
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BBNX
- Director Jones Christy sold $39,354 worth of shares (2,811 units at $14.00) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 27,400 units (SEC Form 4)
- Chief Commercial Officer Hopman Mark sold $3,385 worth of shares (275 units at $12.31) as part of a pre-agreed trading plan, decreasing direct ownership by 0.21% to 130,612 units (SEC Form 4)
- Chief Product Officer Mensinger Mike sold $55,194 worth of shares (4,378 units at $12.61), decreasing direct ownership by 2% to 184,415 units (SEC Form 4) (tax liability)
- Chief Commercial Officer Hopman Mark sold $67,183 worth of shares (5,329 units at $12.61), decreasing direct ownership by 4% to 130,887 units (SEC Form 4) to satisfy withholding tax
- President & CEO Saint Sean sold $212,707 worth of shares (16,872 units at $12.61), decreasing direct ownership by 4% to 420,937 units (SEC Form 4) to cover taxes
- Chief Medical Officer Russell Steven Jon sold $53,227 worth of shares (4,222 units at $12.61), decreasing direct ownership by 2% to 173,849 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Feider Stephen sold $84,165 worth of shares (6,676 units at $12.61), decreasing direct ownership by 4% to 166,053 units (SEC Form 4) to satisfy tax liability
- Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
- Director Palasis Maria was granted 16,965 shares, increasing direct ownership by 136% to 29,397 units (SEC Form 4)
- Director Michel Gerard J was granted 16,965 shares, increasing direct ownership by 103% to 33,509 units (SEC Form 4)
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits